The US Supreme Court has issued its long-awaited decision in Association of Molecular Pathology v. Myriad Genetics, Inc on the patent eligibility of DNA molecules. On its face, the ruling may appear clear cut, but is it? And what will be the effects of the ruling going forward? Our panel will explore the complexity of the issue of DNA patents and the uncertainties raised by the ruling. In a look beyond the specifics, the future implications for the biotech and pharmaceutical sectors will be discussed.